The FDA is set to discuss potential easing of restrictions on peptide compounds, a move that has raised safety concerns among experts and consumer advocates. The newly assembled review panel includes several individuals with ties to the supplement industry and those who have promoted peptides favored by political figure RFK Jr., leading to discussions about conflicts of interest. While some industry representatives, like Olympia Pharmaceuticals, are expressing optimism about opportunities in the peptide market, others are bracing for potential enforcement against peptide ingredients. Despite the FDA staff recommendation that questions the safety of these chemicals, the discussions continue, as panel members include prominent figures from the longevity and wellness medical communities.